Category: 53838-27-0

On March 2, 1990, Agouridas, Constantin; Damais, Chantal; Fauveau, Patrick published a patent.Name: (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate The title of the patent was Preparation of glutamic acid derivatives as immunostimulants. And the patent contained the following:

HO2CCH(NH2)CH2C(:CH2)CH2CH(CO2H)NHCO(CH2)2CH(CO2H)NH-X-CO(CH2)16Me [I; X = bond, Ala], useful as an anticancer agents, antivirals, etc., are prepared E.g., I (X = Ala) was prepared in many steps via condensation of Me2CHCH2OC(O)OC(O)(CH2)2CH(CO2Me)NH-Ala-CO(CH2)16Me with EtO2CCH(NH2)CH2C(:CH2)CH2CH(NHCHO)CO2Et followed by hydrolysis. I stimulated the production of interleukin-1 and tumor necrosis factor in vitro. The experimental process involved the reaction of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate(cas: 53838-27-0).Name: (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate

The Article related to glutamic acid derivative preparation immunostimulant, anticancer glutamic acid derivative, antiviral glutamic acid derivative, Amino Acids, Peptides, and Proteins: Poly(Amino Acids) and Peptides and other aspects.Name: (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On March 25, 2002, Schaschke, Norbert; Dominik, Andreas; Matschiner, Gabriele; Sommerhoff, Christian P. published an article.SDS of cas: 53838-27-0 The title of the article was Bivalent inhibition of β-Tryptase: distance scan of neighboring subunits by dibasic inhibitors. And the article contained the following:

Based on bifunctional diketopiperazines as templates and m-aminomethyl-phenylalanine as arginine mimetic, we have synthesized a new class of structurally related dibasic tryptase inhibitors with systematically increasing spacer length. These compounds were used to scan the distance between the active sites of two neighboring subunits of the β-tryptase tetramer. The Ki-values obtained are a function of the distance between the terminal amino groups and indicate optimal binding of inhibitors with 29-31 bonds between the amino groups. These exptl. data are in full agreement with predictions derived from a novel modeling program that allows the docking of bivalent ligands. The experimental process involved the reaction of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate(cas: 53838-27-0).SDS of cas: 53838-27-0

The Article related to bivalent inhibitor tryptase active site stereochem, Enzymes: Substrates-Cofactors-Inhibitors-Activators-Coenzymes-Products and other aspects.SDS of cas: 53838-27-0

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On September 27, 2007, Koppel, Gary A.; Heindel, Ned D. published a patent.Category: esters-buliding-blocks The title of the patent was Preparation of β-lactamylalkanoic acids as vasopressin V2 antagonists. And the patent contained the following:

β-Lactamylalkanoic acids of formula I [A = carboxylic acid, ester or amide; B = carboxylic acid, ester or amide, (substituted) OH, SH; R1 = H, alkyl; R2 = H, alkyl, alkoxy, alkylthio, CN, CHO, etc.; R3 = (substituted) amino, etc.; R4 = alkyl, alkenyl, cycloalkyl, aryl, etc.] are prepared as vasopressin V2 antagonists. Pharmaceutical compositions containing I are described. Thus, II was prepared, and had IC50 value of 2.06 nM against rat vasopressin V2 receptor. The experimental process involved the reaction of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate(cas: 53838-27-0).Category: esters-buliding-blocks

The Article related to lactamylalkanoic acid preparation vasopressin v2 antagonist, Biomolecules and Their Synthetic Analogs: Beta-Lactam Fungal Metabolites and other aspects.Category: esters-buliding-blocks

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On January 5, 2012, Brownstein, Michael J. published a patent.Recommanded Product: 53838-27-0 The title of the patent was β-Lactam derivatives as vasopressin V1a antagonists and their preparation and use for the treatment of post traumatic stress disorder. And the patent contained the following:

The invention relates to β-lactam derivatives of formula I, which are vasopressin V1a antagonists and which are useful in the treatment of post traumatic stress disorder. Compounds of formula I wherein A is carboxylic acid, ester and amide; B is carboxylic acid, ester, alc., etc.; R1 is H and C1-6 alkyl; R2 is H, alkyl, alkenyl, etc.; R3 is amino, amido, acylamido, etc.; R4 is alkyl, alkenyl, alkynyl, etc.; and pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by a multistep procedure (procedure given). All the invention compounds were evaluated for their vasopressin V1a antagonistic activity and binding affinity. From the assay, it was determined that compound II exhibited a binding affinity IC50 value of 35 nM. The experimental process involved the reaction of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate(cas: 53838-27-0).Recommanded Product: 53838-27-0

The Article related to beta lactam preparation vasopressin v1a antagonist, lactam beta preparation treatment post traumatic stress disorder, Biomolecules and Their Synthetic Analogs: Beta-Lactam Fungal Metabolites and other aspects.Recommanded Product: 53838-27-0

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On February 1, 2018, Veluri, Jagan Mohan Reddy; Mustoori, Sairam; Yeruva, Srinivasulu Reddy; Tapas, Barui; Jyothishwaran, Jyothishwaran; Kanduri, Venkata Sada Siva Rao; Furkhan, Tajamul; Malolanarasimhan, Krishnan; Murugan, Ravichandran Narayanasamy; Kedari, Chaitanyakumar; Vasker, Rakesh Goud; Desai, Sahejad published a patent.Name: (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate The title of the patent was Process for preparation, recovery and purification of lirapeptide as a ubiquitin fusion protein and it’s subsequent conversion to liraglutide. And the patent contained the following:

The present application relates to a process for the preparation of peptides or proteins or derivatives thereof by expression of synthetic oligonucleotide encoding desired protein or peptide in prokaryotic cell as ubiquitin fusion construct. The experimental process involved the reaction of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate(cas: 53838-27-0).Name: (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate

The Article related to lirapeptide sequence ubiquitin fusion protein liraglutide conversion, Fermentation and Bioindustrial Chemistry: Pharmaceuticals (Including Nutrients) and other aspects.Name: (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On December 16, 2009, Metzger, Axel; Qin, Lan-Ying; Cole, Andrew G.; Saionz, Kurt W.; Brescia, Marc-Raleigh; Gstach, Hubert; Wareing, James R.; Zimmermann, Juerg; Brill, Wolfgang K.-D.; Baldwin, John J.; Dolle, Roland E.; Henderson, Ian published an article.Product Details of 53838-27-0 The title of the article was Combined solution-phase and solid-phase synthesis of 2-amino-7,8-dihydropteridin-6(5H)-ones. And the article contained the following:

An efficient and general synthesis of substituted 2-amino-7,8-dihydropteridin-6(5H)-ones I [R1 = i-Bu, MeOCH2CH2, Ph, 3,4-Cl2C6H3, PhCH2CH2; R2 = Me, HOCH2, HO2CCH2CH2, H2N(CH2)4, 4-HOC6H4CH2; R3 = Ph, 4-ClC6H4, 3-pyridyl, etc.] using a combination of solution-phase and solid-phase chem. is described. Solution-phase chem. was used to produce two pyrimidine regioisomers that were separated by flash column chromatog. Utilizing the desired regioisomer II, solid-phase chem. was used to effect the rapid construction of the substituted 2-amino-7,8-dihydropteridin-6(5H)-one system in high overall yield and purity. The experimental process involved the reaction of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate(cas: 53838-27-0).Product Details of 53838-27-0

The Article related to pteridinone amino dihydro solution solid phase synthesis, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Product Details of 53838-27-0

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On June 30, 2008, Gellerman, G.; Hazan, E.; Brider, T.; Traube, T.; Albeck, A.; Shatzmiler, S. published an article.Quality Control of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate The title of the article was Facile Synthesis of Orthogonally Protected Optically Pure Keto- and Diketopiperazine Building Blocks for Combinatorial Chemistry. And the article contained the following:

A simple and convenient synthesis of orthogonally protected multi-tethered, optically pure 2-ketopiperazine and 2,5-diketopiperazine scaffolds for Fmoc and Boc combinatorial chem. was achieved, starting from accessible chiral amino acid precursors, by sequentially utilizing reductive alkylation, dipeptide coupling and ketopiperazine ring formation as key steps. These scaffolds can introduce valuable drug-like properties in three independent directions to any medicinally relevant piperazine-based motif by “around the scaffold” drug optimization. In addition, these building blocks have a wide application scope in managing fast and efficient multi-cyclic optimization processes in the combinatorial chem. and drug design fields. The experimental process involved the reaction of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate(cas: 53838-27-0).Quality Control of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate

The Article related to chiral amino acid reduction alkylation coupling ring formation heterocyclization, keto diketopiperazine stereoselective preparation combinatorial chem, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Quality Control of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On December 2, 1997, Gilbert, Kevin; Williams, Peter D.; Evans, Ben E.; Hobbs, Doug W.; Veber, Daniel F. published a patent.Related Products of 53838-27-0 The title of the patent was Preparation of hydantoin and succinimide-substituted derivatives of spiroindanylcamphorsulfonylamides for use as oxytocin and vasopressin antagonists. And the patent contained the following:

Camphorsulfonylamides I and II [R = heterocyclyl such as imidazolyl, pyrrolidinyl, piperidinyl, piperazinyl, maleimido; R1 = H; R1R1 = bond] were prepared as oxytocin and vasopressin antagonists useful in the treatment of preterm labor, dysmenorrhea, and for the stoppage of labor preparatory to Cesarean delivery. Thus, endo-I [R = maleimido, R1 = H] was prepared starting from bis(2-chloroethyl)amine dihydrochloride, indene, (+)-10-camphorsufonyl chloride, and maleic anhydride and showed 70% inhibition of specific binding at 1000 nM in the [3H]OT binding assay. The experimental process involved the reaction of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate(cas: 53838-27-0).Related Products of 53838-27-0

The Article related to camphorsulfonylamide preparation oxytocin receptor antagonist, vasopressin receptor antagonist spiroindanylcamphorsulfonylamide preparation, Terpenes and Terpenoids: Monoterpenes (C10), Including Cannabinoids, Chrysanthemic Acids, and Iridoid Aglycons and other aspects.Related Products of 53838-27-0

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On April 22, 2004, Shi, Qian; Wang, Hui-kang; Oyama, Masayoshi; Vance, John Robert; Chen, Ming S. published a patent.Synthetic Route of 53838-27-0 The title of the patent was Preparation of podophyllotoxin derivatives as anticancer compounds. And the patent contained the following:

Podophyllotoxin derivatives, such as I [R1, R2, R3, R7 = H, alkyl; R4, R6 = alkyl; R5 = H, P(O)(ORa)2; Ra = H, alkyl; T = H; XT = :N; X = bond, O, S, NRb; Rb = H, alkyl; Y = 5-membered heteroaryl or heterocyclyl, optionally substituted with one or more halogen, alkyl, cyclyl, aryl, heteroaryl, heterocyclyl, etc.], were prepared for their therapeutic use as anticancer agents. Thus, podophyllotoxin derivative II was prepared via a multistep synthetic sequence starting from 4′-demethyl-4β-bromo-4-desoxypodophyllotoxin (prepared from podophyllotoxin), 2-aminothiazole-4-acetic acid and (trimethylsilyl)diazomethane. II showed unexpectedly high levels of cellular protein-linked DNA breaks (PLDB) induction in KB cells when tested at 5μg/mL. This invention also features a method for treating cancer. The experimental process involved the reaction of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate(cas: 53838-27-0).Synthetic Route of 53838-27-0

The Article related to podophyllotoxin derivative preparation anticancer, Biomolecules and Their Synthetic Analogs: Others, Including Purines, Pyrimidine Nucleic Acid Bases, Flavins, Lignans and other aspects.Synthetic Route of 53838-27-0

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On November 13, 2014, Guo, Xialing; Zhu, Zhen published a patent.Product Details of 53838-27-0 The title of the patent was Thienopyridine compounds as tyrosine kinase modulators and their preparation. And the patent contained the following:

The invention is directed to compounds of formula I that are potent tyrosine kinase modulators, and are suitable for the treatment and prevention of diseases and conditions related to abnormal activities of tyrosine kinase receptors. Compounds of formula I wherein X is NH and derivatives O, and SO0-3; n is 0 – 3; m is 0 – 2; R1 is H, halo, C1-8 alkyl, etc.; R2 is H, alkoxy, alkoxyalkoxy, alkyl, etc.; R3 is (un)substituted C1-5 alkyl, (un)branched C1-5 haloalkyl, C1-5 alkoxy, etc.; R4 is (un)substituted alkoxy, alkoxyalkyl, alkoxycarbonyl, etc.; Y is (CH2)0-3O(CH2)0-3, (CH2)0-4NH(CH2)0-3 and derivatives; (CH2)0-3CO(CH2)0-3, etc.; A and B are independently Ph, naphthyl, 5- to 6-membered heteroaryl, etc.; Z is (CH2)0-1NHCONH(CH)0-1 and derivatives, (CH2)0-1NHCSNH(CH)0-1 and derivatives, (CH2)0-1NHCO and derivatives, etc.; and pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by etherification of Me 7-bromothieno[3,2-b]pyridine-2-carboxylate with 4-aminophenol; the resulting Me 7-(4-aminophenoxy)thieno[3,2-b]pyridine-2-carboxylate underwent addition to 2-fluoro-5-methylphenyl isocyanate to give compound II. All the invention compounds were evaluated for their tyrosine kinase modulatory activity. From the assay, it was determined that compound II exhibited IC50 values in the range of 2 nM to 18 nM toward VEGFR2. The experimental process involved the reaction of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate(cas: 53838-27-0).Product Details of 53838-27-0

The Article related to thienopyridine preparation tyrosine kinase modulator, Heterocyclic Compounds (More Than One Hetero Atom): Fused-Ring Systems With Two Or More Hetero Atoms, No More Than One Hetero Atom Per Ring and other aspects.Product Details of 53838-27-0

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics